Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 406 across all filing types
Latest filing 2026-06-05 Director's Dealing
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 89% confidence The document is a statutory filing to the Korean Financial Services Commission and Korea Exchange by a company insider (황금민) detailing personal holdings and changes in ownership of the company’s securities. It lists shareholding counts, ratios, and transaction details for an executive. This matches an insider director’s dealing report. Therefore, it falls under the “Director’s Dealing” category (DIRS).
2026-06-05 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled '분기보고서' which translates to 'Quarterly Report' and specifies the period from January 1, 2026 to March 31, 2026, indicating it covers a quarter of the fiscal year. It contains detailed financial and operational information such as sales, production capacity, research and development activities, and contracts. The length is about 15,000 characters, which is substantial and contains actual financial data and analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 91% confidence The document is a Korean “주식등의 대량보유상황보고서(일반)” under the Capital Markets Act – a detailed notification of large shareholdings by a major shareholder and related parties, including share counts, ratios, changes, and underlying contracts. This matches our category for Major Shareholding Notifications (Code: MRQ).
2026-04-09 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is titled “정기주주총회결과” (“Regular General Meeting of Shareholders Results”) and provides detailed voting outcomes (approval/rejection percentages) for each agenda item at the AGM, including resolutions on financial statements, director and auditor appointments, and amendments. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-03-24 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Gencurix' (주식회사 젠큐릭스) for the fiscal year ending December 31, 2025. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial document, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR). FY 2025
2026-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, key financial data, and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a specific regulatory disclosure of the audit report's submission rather than the full annual report (10-K) or a simple announcement of publication (RPA). Given the specific nature of audit report filings in the Korean market, 'AR' (Audit Report / Information) is the most accurate classification. FY 2025
2026-03-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.